Cancer in Croatia

IARC estimates 26,955 new cancer cases and 13,573 cancer deaths in Croatia in 2024; the commonest new cancers are colorectum, trachea, bronchus and lung and breast. This page is assembled automatically from OnCo's data: 46 trials with a site there, 1 institution, 1 person and 1 programme or law, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

26,955

all cancers

Deaths

13,573

all cancers

Incidence rate

311.8

per 100,000, age-standardised

Mortality rate

123.4

per 100,000, age-standardised

Cumulative risk

30.3%

of a cancer by age 74

Population

3,875,329

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Colorectum	3,926	39.9	Colorectal cancer
Trachea, bronchus and lung	3,491	36.0	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Breast	3,040	78.7	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	2,872	64.0	Prostate cancer
Bladder	1,347	13.4	Bladder & urothelial cancer
Melanoma of skin	1,070	13.9	Melanoma
Stomach	972	9.2	Gastric & gastro-oesophageal junction cancer
Kidney	950	11.7	Renal cell carcinoma
Pancreas	885	8.3	Pancreatic ductal adenocarcinoma
Thyroid	782	16.1	Thyroid cancer

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	2,864	28.4	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	2,280	18.8	Colorectal cancer
Prostate	923	15.9	Prostate cancer
Pancreas	793	7.1	Pancreatic ductal adenocarcinoma
Stomach	669	5.8	Gastric & gastro-oesophageal junction cancer
Bladder	547	4.0	Bladder & urothelial cancer
Breast	508	11.0	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Liver and intrahepatic bile ducts	502	4.5	Hepatocellular carcinoma
Brain, central nervous system	404	5.1	Glioma & glioblastoma
Leukaemia	394	3.5	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Croatia”, in Southern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

46 trials in OnCo · 9 recruiting overall

46 trials

Trial			Lead sponsor
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma NCT05645107	Phase 3	Recruiting	Grifols Therapeutics LLC	62	2026-09-30
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC NCT04892173	Phase 3	Recruiting	Johnson & Johnson Enterprise Innovation Inc.	193	2026-09-25
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) NCT06875310	Phase 3	Recruiting	Mirati Therapeutics Inc.	351	2026-09-22
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G NCT04613596	Phase 2/3	Recruiting	Mirati Therapeutics Inc.	770	2026-09-16
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other NCT06152575	Phase 3	Recruiting	Pfizer	270	2026-08-24
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) NCT07227402	Phase 3	Recruiting	Merck Sharp & Dohme LLC	127	2026-08-03
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC NCT05491525	Phase 2/3	Recruiting	Urovant Sciences GmbH	38	2026-06-15
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients NCT04844866	Phase 2	Recruiting	Miltenyi Biomedicine GmbH	51	2026-06-10
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera NCT06093672	Phase 3	Recruiting	Italfarmaco	90	2026-03-25
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) NCT06635824	Phase 3	Active not recruiting	Genmab	247	2026-10-06
LITESPARK-012 NCT04736706	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	262	2026-10-02
SPOTLIGHT & GLOW NCT03504397, NCT03653507	Phase 3	Active not recruiting	Astellas Pharma Global Development, Inc.	385	2026-09-28
LiGeR-HN1 NCT06525220	Phase 3	Active not recruiting	Merus B.V.	202	2026-09-25
EPCORE DLBCL-2 NCT05578976	Phase 3	Active not recruiting	Genmab	331	2026-09-11
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) NCT05853575	Phase 2	Active not recruiting	Mirati Therapeutics Inc.	98	2026-08-14
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases NCT04603807	Phase 3	Active not recruiting	Hoffmann-La Roche	61	2026-08-13
CAMBRIA-1 & CAMBRIA-2 NCT05952557	Phase 3	Active not recruiting	AstraZeneca	661	2026-08-10
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease NCT06191744	Phase 3	Active not recruiting	Genmab	266	2026-08-04
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL NCT02970318	Phase 3	Active not recruiting	Acerta Pharma BV	157	2026-07-24
EV-304 / KEYNOTE-B15 NCT04700124	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	188	2026-07-16
lidERA NCT04961996	Phase 3	Active not recruiting	Hoffmann-La Roche	622	2026-06-17
VIALE-A NCT02993523	Phase 3	Active not recruiting	AbbVie	172	2026-06-11
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma ( NCT05429268	Phase 3	Active not recruiting	Incyte Corporation	61	2026-05-05
BRUIN CLL-321 NCT04666038	Phase 3	Active not recruiting	Loxo Oncology, Inc.	232	2026-04-24
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita NCT06508658	Phase 3	Active not recruiting	Genmab	176	2026-04-08
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy NCT06726265	Phase 3	Active not recruiting	Immutep S.A.S.	147	2026-03-18
PANOVA-3 NCT03377491	Phase 3	Completed	NovoCure Ltd.	199	2026-01-21
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma NCT06054555	Phase 3	Active not recruiting	Amgen	180	2026-01-12
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis NCT04468984	Phase 3	Active not recruiting	AbbVie	229	2026-01-09
APHINITY NCT01358877	Phase 3	Completed	Hoffmann-La Roche	546	2025-11-28

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Croatia, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Croatia is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

1 institution

University Hospital for Tumors, Sestre milosrdnice University Hospital Centre

1 person

People whose main affiliation in OnCo is an institution or company in Croatia.

Robert Šeparović

Screening, vaccination and law

Term

Lung cancer screening programme in Croatia

Croatia runs a national, fully reimbursed lung cancer screening programme with low-dose CT, in which family doctors refer people at high risk; more than 50,000 people were screened from October 2020 to August 2025.

Approvals

Croatia is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Croatia's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Croatia, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Croatia's own sources, beyond the programme records above.

Croatia is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/hr.json; every country: /api/v1/countries.json.